Assembly Biosciences Announces Upcoming Investor Conference Participation
Assembly Biosciences (Nasdaq: ASMB) will participate in two investor conference fireside chats in October–November 2025.
Anuj Gaggar, MD, PhD, chief medical officer, will appear in a pre-recorded fireside chat available on demand beginning October 21, 2025 at 7:00 AM ET during the H.C. Wainwright Liver Disease Virtual Conference.
Jason Okazaki, CEO and president, and Dr. Gaggar will present a live fireside chat on November 12, 2025 at 11:00 AM ET at the Guggenheim 2nd Annual Healthcare Innovation Conference. Webcasts and replays will be available via the company's Events and Presentations page.
Assembly Biosciences (Nasdaq: ASMB) parteciperà a due conversazioni informali con investitori nel corso di ottobre–novembre 2025.
Anuj Gaggar, MD, PhD, chief medical officer, apparirà in una chiacchierata informale preregistrata disponibile on demand a partire dal October 21, 2025 at 7:00 AM ET durante la H.C. Wainwright Liver Disease Virtual Conference.
Jason Okazaki, CEO e presidente, e il Dott. Gaggar terranno una chiacchierata informale dal vivo il November 12, 2025 at 11:00 AM ET durante la Guggenheim 2nd Annual Healthcare Innovation Conference. Le webcast e le repliche saranno disponibili tramite la pagina Eventi e Presentazioni dell'azienda.
Assembly Biosciences (Nasdaq: ASMB) participará en dos conversaciones informales para inversores (fireside chats) en octubre–noviembre de 2025.
Anuj Gaggar, MD, PhD, director médico, aparecerá en una charla informal prerecordada disponible bajo demanda a partir del 21 de octubre de 2025 a las 7:00 AM ET durante la Conferencia Virtual de Enfermedades Hepáticas de H.C. Wainwright.
Jason Okazaki, director general y presidente, y el Dr. Gaggar presentarán una charla informal en vivo el 12 de noviembre de 2025 a las 11:00 AM ET en la Guggenheim 2ª Conferencia Anual sobre Innovación en el Cuidado de la Salud. Las transmisiones web y las repeticiones estarán disponibles a través de la página de Eventos y Presentaciones de la empresa.
Assembly Biosciences (Nasdaq: ASMB)은 2025년 10월~11월 두 차례의 투자자 컨퍼런스 파이어사이드 채팅에 참여합니다.
Anuj Gaggar, MD, PhD 최고의료책임자는 사전 녹화된 파이어사이드 채팅에 출연하며 수요에 따라 이용 가능하며 시작일은 2025년 10월 21일 동부표준시 7:00 AM에 H.C. Wainwright 간 Liver Disease Virtual Conference에서 진행됩니다.
Jason Okazaki CEO 겸 사장 및 Gaggar 박사는 2025년 11월 12일 동부표준시 11:00 AM에 Guggenheim 2nd Annual Healthcare Innovation Conference에서 라이브 파이어사이드 채팅을 발표합니다. 웹캐스트 및 재방송은 회사의 이벤트 및 발표 페이지에서 이용 가능합니다.
Assembly Biosciences (Nasdaq: ASMB) participera à deux conversations informelles avec des investisseurs (fireside chats) en octobre–novembre 2025.
Anuj Gaggar, MD, PhD, directeur médical, apparaîtra lors d'une session informelle préenregistrée disponible à la demande à partir du 21 octobre 2025 à 7h00 ET pendant la conférence virtuelle sur les maladies hépatiques de H.C. Wainwright.
Jason Okazaki, CEO et président, et le Dr Gaggar présenteront une session informelle en direct le 12 novembre 2025 à 11h00 ET lors de la Guggenheim 2e Conférence annuelle sur l'innovation en soins de santé. Les webcasts et les rediffusions seront disponibles via la page Événements et Présentations de l'entreprise.
Assembly Biosciences (Nasdaq: ASMB) wird im Oktober–November 2025 an zwei Investorenkonferenzen teilnehmen, bei denen Fireside Chats stattfinden.
Anuj Gaggar, MD, PhD, Chief Medical Officer, wird in einer vorab aufgezeichneten Fireside-Chat erscheinen, die auf Abruf ab dem 21. Oktober 2025 um 7:00 Uhr ET während der H.C. Wainwright Liver Disease Virtual Conference verfügbar sein wird.
Jason Okazaki, CEO und Präsident, und Dr. Gaggar führen eine Live-Fireside-Chat am 12. November 2025 um 11:00 Uhr ET bei der Guggenheim 2nd Annual Healthcare Innovation Conference durch. Webcasts und Wiederholungen werden über die Webseite des Unternehmens "Events and Presentations" verfügbar sein.
Assembly Biosciences (Nasdaq: ASMB) ستشارك في محادثات الحوار الجانبي (fireside chats) لمؤتمرين للمستثمرين في أكتوبر–نوفمبر 2025.
Anuj Gaggar, MD, PhD، المدير الطبي، سيظهر في محادثة حوار جانبي مسجلة مسبقاً ومتاحة عند الطلب بدءاً من 21 أكتوبر 2025 الساعة 7:00 صباحاً بتوقيت شرق الولايات المتحدة خلال المؤتمر الافتراضي لأمراض الكبد لدى H.C. Wainwright.
Jason Okazaki، الرئيس التنفيذي ورئيس مجلس الإدارة، وDr. Gaggar سيقدمان محادثة حوار جانبي مباشرة في 12 نوفمبر 2025 الساعة 11:00 صباحاً بتوقيت شرق الولايات المتحدة في مؤتمر Guggenheim السنوي الثاني للابتكار في الرعاية الصحية. ستتوفر البثوث عبر الإنترنت وإعادة العروض عبر صفحة الأحداث والعروض الخاصة بالشركة.
Assembly Biosciences (Nasdaq: ASMB) 将在2025年10月至11月参加两场投资者会议的炉边对谈(fireside chats)。
Anuj Gaggar, MD, PhD,首席医疗官,将在可按需观看的预录炉边对谈中出席,2025年10月21日 东部时间7:00 AM,于 H.C. Wainwright Liver Disease Virtual Conference 期间。
Jason Okazaki,CEO兼总裁,与 Gaggar 博士将于 2025年11月12日 东部时间11:00 AM 在 Guggenheim 第2届年度 Healthcare Innovation Conference 上进行现场炉边对谈。公司的活动与演示页面将提供 webcast 与重播。
- None.
- None.
SOUTH SAN FRANCISCO, Calif., Oct. 14, 2025 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a biotechnology company developing innovative therapeutics targeting serious viral diseases, today announced that the company will participate in fireside chats at two upcoming investor conferences.
H.C. Wainwright Liver Disease Virtual Conference
Anuj Gaggar, MD, PhD, chief medical officer, will present in a pre-recorded fireside chat that will be available on demand during the H.C. Wainwright Liver Disease Virtual Conference starting at 7 a.m. Eastern Time on October 21, 2025.
Guggenheim 2nd Annual Healthcare Innovation Conference
Jason Okazaki, chief executive officer and president, and Dr. Gaggar will present in a fireside chat during the Guggenheim 2nd Annual Healthcare Innovation Conference at 11 a.m. Eastern Time on November 12, 2025.
To register for either webcast, please visit the Events and Presentations section of Assembly Bio’s website at: https://investor.assemblybio.com/events-presentations. A replay will be accessible following each event.
About Assembly Biosciences
Assembly Biosciences is a biotechnology company dedicated to the development of innovative small-molecule therapeutics designed to change the path of serious viral diseases and improve the lives of patients worldwide. Led by an accomplished team of leaders in virologic drug development, Assembly Bio is committed to improving outcomes for patients struggling with the serious, chronic impacts of herpesvirus, hepatitis B virus (HBV) and hepatitis delta virus (HDV) infections. For more information, visit assemblybio.com.
Forward-Looking Statements
The information in this press release contains forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to materially differ. These risks and uncertainties include: Assembly Bio’s ability to maintain financial resources and secure additional funding necessary to continue its research activities, clinical studies, and other business operations; Assembly Bio’s ability to realize the potential benefits of its collaboration with Gilead Sciences, Inc. (Gilead), including all financial aspects of the collaboration and equity investments; Assembly Bio’s ability to initiate and complete clinical studies involving its therapeutic product candidates, including studies contemplated by Assembly Bio’s collaboration with Gilead, in the currently anticipated timeframes or at all; safety and efficacy data from clinical or nonclinical studies may not warrant further development of Assembly Bio’s product candidates; clinical and nonclinical data may not differentiate Assembly Bio’s product candidates from other companies’ candidates; potential effects of changes in government regulation, including as a result of the change in U.S. administration in 2025; results of nonclinical studies may not be representative of disease behavior in a clinical setting and may not be predictive of the outcomes of clinical studies; and other risks identified from time to time in Assembly Bio’s reports filed with the U.S. Securities and Exchange Commission (the SEC). You are urged to consider statements that include the words may, will, would, could, should, might, believes, hopes, estimates, projects, potential, expects, plans, anticipates, intends, continues, forecast, designed, goal or the negative of those words or other comparable words to be uncertain and forward-looking. Assembly Bio intends such forward-looking statements to be covered by the safe harbor provisions contained in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. More information about Assembly Bio’s risks and uncertainties are more fully detailed under the heading “Risk Factors” in Assembly Bio’s filings with the SEC, including its most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. Except as required by law, Assembly Bio assumes no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise.
Contacts
Investor and Corporate:
Shannon Ryan
SVP, Investor Relations, Corporate Affairs and Alliance Management
(415) 738-2992
investor_relations@assemblybio.com
Media:
Sam Brown LLC
Alyssa Kuciunas
(331) 481-3751
ASMBMedia@sambrown.com
